Clinical Trial Update: A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CIML NK cell infusion for relapse of myeloid disease after hematopoietic cell transplantation; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Juvenile Myelomonocytic Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• CIML NK Cell Infusion

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: RECRUITING